GUILD Learning and Development has partnered with Reckitt Benckiser in the development of a new CPD-accredited online course titled Reviewing the gastrointestinal tolerability of ibuprofen.
The course looks at interactions between non-steroidal anti inflammatory drugs (NSAIDs) and the gastrointesinal tract.
"NSAIDs are among the most widely used medicines in the world and gastrointestinal toxicity is the most common adverse affect associated with their use," the Guild said.
The risk of GI adverse effects occurring is dependent on the NSAID, dosage and individual patient factors.
"It therefore is important that pharmacists consider the tolerability profile of each individual NSAID, rather than assuming an overall class effect," with the course looking at factors impacting GI tolerability of NSAIDs and the safety profile of ibuprofen versus other analgesics.
The activity has been accredited for 0.75 hours of Group 1 CPD, suitable for inclusion in an individual pharmacist's CPD plan.
That can be converted into 1.5 CPD credits upon successful completion of relevant assessment activities - to enrol in the course see www.myCPD.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Nov 17
